AN2 Therapeutics, Inc. (ANTX): Shareholders' Equity
$53.06M
As of 2025-12-31
$75.92M
As of 2026-06-30
-17.8%
3-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $53.06M | -35.2% | 2026-03-17, Balance as of period end |
| 2024-12-31 | $81.85M | -34.4% | 2026-03-17, Balance as of period end |
| 2023-12-31 | $124.70M | +30.8% | 2025-03-25, Balance as of period end |
| 2022-12-31 | $95.37M | n/m | 2024-03-29, Balance as of period end |
| 2021-12-31 | -$47.41M | n/a | 2023-03-29, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | 2025-12-31 | $53.06M | -35.2% |
| Lifevantage Corp (LFVN) | 2026-06-30 | $33.59M | -3.0% |
| OnKure Therapeutics, Inc. (OKUR) | 2025-12-31 | $56.18M | -45.9% |
| Q32 Bio Inc. (QTTB) | 2025-12-31 | $42.01M | +640.3% |
| Rallybio Corp (RLYB) | 2025-12-31 | $57.96M | -6.0% |
| DiaMedica Therapeutics Inc. (DMAC) | 2025-12-31 | $56.11M | +37.8% |
| Pasithea Therapeutics Corp. (KTTA) | 2025-12-31 | $55.22M | +273.5% |
| ProPhase Labs, Inc. (PRPH) | 2025-12-31 | $3.51M | -52.3% |
| Palvella Therapeutics, Inc. (PVLA) | 2025-12-31 | $27.98M | -55.3% |
Compare ANTX, LFVN, OKUR, QTTB side by side · Screen every company in Pharmaceutical Preparations ↗